China Healthcare Select

Chinese biotech company Hoyotek Biomedical has disclosed that its experimental anti-amyloid-beta monoclonal antibody 6C3 demonstrated plaque-clearing efficacy comparable to Eli Lilly's recently approved Alzheimer's drug donanemab in head-to-head preclinical tests, without any molecular optimization. In 5×FAD transgenic mouse models, 6C3 showed approximately a 40% reduction in amyloid-beta plaque count and a 50% reduction in plaque area, with no statistically significant difference from donanemab. Beyond its drug pipeline, Hoyotek has established a unique integrated 'Diagnostics + New Drug' model in China, holding registration certificates for eight core Alzheimer's biomarkers for early screening. This dual-track strategy positions 6C3 as a highly competitive domestic candidate that could eventually cost one-third of imported therapies priced at 200,000–300,000 yuan annually, potentially addressing the immense clinical needs of China's over 10 million Alzheimer's patients.

On September 9, 2026, BMDEVICE (Hainan Biomedical Device Co., Ltd.) officially listed on the Beijing Stock Exchange (BSE). Its shares opened at RMB 32.86, surging 92%, with a market capitalization of about RMB 1.7 billion. As of press time, the share price had pulled back to RMB 27.84 in real time, up 62.81%, with total market capitalization exceeding RMB 1.5 billion. Proceeds from this BSE IPO will be used mainly for capacity expansion. The capacity for Fengchuangling is expected to reach 3.25 million pieces, antibacterial fishbone sutures 250,000 pieces, and antibacterial barbed sutures 500,000 pieces. Capacity for absorbable surgical sealing adhesive and skin wound adhesive will also be added.

Amgen and AstraZeneca announced that combining their targeted immunotherapies, Imdelltra and Imfinzi, significantly improved overall survival, progression-free survival, and response rates in patients with extensive-stage small cell lung cancer. The late-stage clinical trial evaluated the drug pairing as a maintenance therapy following standard induction treatment, demonstrating meaningful benefits over Imfinzi alone with no new safety concerns. These findings represent a potential breakthrough for treating a highly aggressive and deadly form of lung cancer with historically low survival rates.

Unike (Hangzhou) Biopharmaceutical Technology Co., Ltd. recently completed a tens-of-millions RMB angel financing round. The round was led by Longhope Capital, with the Riemann Hypothesis serving as the exclusive financial advisor. Unike is an innovative pharmaceutical company driven by cutting-edge proprietary technologies. Leveraging its ZT long-acting protein and peptide proprietary technology platform, the company is dedicated to addressing industry pain points such as the short half-life and poor stability of protein and peptide drugs. The funds raised in this round will be primarily invested in the research and development, validation, and clinical trial applications of innovative drug pipelines based on its core technology platform. This aims to comprehensively accelerate the R&D process and industrialization of the company’s long-acting protein and peptide drugs, promoting the translation of high-quality innovative drugs with independent intellectual property rights.

EBV, the first virus linked to tumors, lies latent in over 90% of adults and is tied to nasopharyngeal carcinoma, lymphoma, and multiple sclerosis — yet no specific drug is approved globally. Hotspots in Africa and South China left the field overlooked by Western academia with scarce R&D. As the EBV–MS link was confirmed, giants including Moderna entered the race. China accounts for 45% of global EBV-related tumor deaths and nearly 40% of nasopharyngeal carcinoma cases. CBNOVA Medical Technology now stands out, built on 20-plus years of work by Sun Yat-sen University Cancer Center's academician-led team (80+ papers, 40+ patents), breaking the traditional biotech model to tackle this neglected public health problem and deliver innovative EBV solutions for China and beyond.

In summer 2026, Hong Kong’s medical AI sector attracted growing investor attention. Brainsmart Technology completed an angel round exceeding $10 million, led by Bayland Capital with participation from BlueRun Ventures, to fund electrode R&D and a GMP-compliant production line in Shenzhen. AilsynBio secured seed funding from the Gobi–HKU Fund to accelerate AI-driven drug discovery and has partnered with Dong-E-E-Jiao. Psyrene Technology also raised several million yuan in seed funding, focusing on home-based management of chronic and mental disorders. These deals highlight rising competition among mainland Chinese investors for university spinouts founded by doctoral researchers in Hong Kong. Startups from HKUST and HKU are also raising capital across areas including embodied intelligence, reinforcing Hong Kong’s emergence as a new hub for medical AI entrepreneurship.